» Articles » PMID: 26850415

Serum Levels of the Bone Turnover Markers Dickkopf-1, Sclerostin, Osteoprotegerin, Osteopontin, Osteocalcin and 25-hydroxyvitamin D in Swedish Geriatric Patients Aged 75 years or Older with a Fresh Hip Fracture and in Healthy Controls

Overview
Publisher Springer
Specialty Endocrinology
Date 2016 Feb 7
PMID 26850415
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bone turnover markers have a potential clinical use in describing bone remodeling and in predicting fractures.

Aims: In an elderly population ≥75 years with a fresh hip fracture, and in healthy controls, investigate bone turnover markers and their relation to each other, to vitamin D status and to bone mineral density (BMD).

Methods: In a cross-sectional study serum levels of dickkopf-1 (DKK-1), sclerostin (SOST), osteoprotegerin (OPG), osteopontin (OPN), osteocalcin, 25-hydroxyvitamin D (25(OH)D) were analyzed in 89 Swedish patients with a fresh hip fracture and in 82 healthy volunteers. Serum levels of bone markers were determined by Luminex technique.

Results: S-25-hydroxyvitamin D (S-25(OH)D) was decreased in patients compared to controls (48 ± 21 vs. 76 ± 25 nmol/L, p < 0.001). SOST, but none of the other bone turnover markers correlated with BMD (r = 0.50, p < 0.001). Compared with controls, higher levels of OPG (488 ± 1.4 vs. 191 ± 1.4 ng/L, p < 0.001), OPN (69 ± 1.7 vs. 19 ± 1.4 µg/L, p < 0.001), DKK-1 (273 ± 1.7 vs. 168 ± 1.7 ng/L, p < 0.001), and lower levels of osteocalcin (5.8 ± 3.5 vs. 9.5 ± 3.6 µg/L, p < 0.001), were found in the fracture group. Levels of OPG, DKK-1 and SOST in both groups were positively associated. S-25(OH)D concentration was not found to be strongly associated with any of the bone markers.

Conclusions: In contrast to findings in other studies, we found no strong correlation between 25(OH)D and the investigated bone markers. Both in patients with a fresh hip fracture and in healthy elderly, DKK-1, SOST and OPG appear to be associated. This suggests a relevance in these relationships meriting further investigation.

Citing Articles

Role of sclerostin in mastocytosis bone disease.

Szudy-Szczyrek A, Mlak R, Pigon-Zajac D, Krupski W, Mazurek M, Tomczak A Sci Rep. 2025; 15(1):161.

PMID: 39747949 PMC: 11697018. DOI: 10.1038/s41598-024-83851-0.


Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.

Halupczok-Zyla J, Jawiarczyk-Przybylowska A, Bolanowski M Front Endocrinol (Lausanne). 2025; 15:1472680.

PMID: 39741885 PMC: 11685073. DOI: 10.3389/fendo.2024.1472680.


Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.

Martiniakova M, Mondockova V, Kovacova V, Babikova M, Zemanova N, Biro R Diabetol Metab Syndr. 2024; 16(1):217.

PMID: 39238022 PMC: 11378428. DOI: 10.1186/s13098-024-01440-7.


Nutrition, Vitamin D, and Calcium in Elderly Patients before and after a Hip Fracture and Their Impact on the Musculoskeletal System: A Narrative Review.

Cianferotti L, Bifolco G, Caffarelli C, Mazziotti G, Migliaccio S, Napoli N Nutrients. 2024; 16(11).

PMID: 38892706 PMC: 11174536. DOI: 10.3390/nu16111773.


Association of serum sclerostin levels with marrow adiposity in postmenopausal women with glucocorticoid-induced osteoporosis.

Li W, Wang W, Zhang M, Chen Q, Li F, Li S BMC Endocr Disord. 2024; 24(1):55.

PMID: 38679740 PMC: 11056049. DOI: 10.1186/s12902-024-01591-8.


References
1.
Pinzone J, Hall B, Thudi N, Vonau M, Qiang Y, Rosol T . The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2008; 113(3):517-25. PMC: 2628360. DOI: 10.1182/blood-2008-03-145169. View

2.
Chang I, Chiang T, Yeh K, Lee H, Cheng Y . Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int. 2010; 21(8):1401-9. DOI: 10.1007/s00198-009-1107-7. View

3.
Wang X, Zhang Y, Yu Z, Zhou J . The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients. Mol Med Rep. 2013; 7(4):1169-72. DOI: 10.3892/mmr.2013.1335. View

4.
Jemtland R, Holden M, Reppe S, Olstad O, Reinholt F, Gautvik V . Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res. 2011; 26(8):1793-801. DOI: 10.1002/jbmr.396. View

5.
Dovjak P, Dorfer S, Foger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P . Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014; 60(6):493-501. DOI: 10.1159/000358303. View